二甲双胍与格列美脲对早期糖尿病肾病患者纤溶酶原活性的作用 |
| |
引用本文: | 郭冠芬,张秀薇,刘玉华,刘衬连.二甲双胍与格列美脲对早期糖尿病肾病患者纤溶酶原活性的作用[J].中国现代医生,2014(11):138-139,142. |
| |
作者姓名: | 郭冠芬 张秀薇 刘玉华 刘衬连 |
| |
作者单位: | 广东省东莞市人民医院内分泌科,广东东莞523000 |
| |
摘 要: | 目的 探讨二甲双胍、格列美脲对早期糖尿病肾病患者组织纤溶酶原激活剂(t-PA)及纤溶酶原激活物抑制剂-1(PAI-1)水平的影响.方法 60例早期糖尿病肾病患者分为两组,分别接受格列美脲、二甲双胍治疗,比较两组治疗3个月前后患者血糖控制情况及血t-PA、PAI-1水平的变化.结果 与治疗前相比,治疗后两组患者的FPG、HOMA指数均明显下降,血T-PA水平明显升高,同时血PAI-1水平显著下降,差异有统计学意义(P<0.05).结论 二甲双胍、格列美脲对早期糖尿病肾病患者除改善血糖控制外,还能改善患者的纤溶系统功能.
|
关 键 词: | 格列美脲 二甲双胍 糖尿病肾病 纤溶酶原激活剂抑制物-1 组织纤溶酶原激活剂 |
Effects of metformin and glimepiride on plasminogen activity in early patients with diabetic nephropathy |
| |
Authors: | GUO Guanfen ZHANG Xiuwei LIU Yuhua LIU Chenlian |
| |
Affiliation: | (Endocrinology Diseases Department, Dongguan People' s Hospital, Dongguan 523000, China) |
| |
Abstract: | Objective To study the effects of metformin and glimepiride on tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in early diabetic nephropathy(DN) patients. Methods Sixty DN patients were divided into two groups and received glimepiride or metformin trearment respectively for 3 months. The glycemic control and the level of serum t-PA and PAI-1 before and 3 months after treatment were observed. Results After 3 months with metformin or glimepiride treatment, the FPG level and HOMA index were significantly lower, and there was significant promotion in the level of serum t-PA and reductions in the level of serum PAI-1. Conclusion Both glimepiride and metformin can improve glycemic control and plasminogen activity in early DN patients. |
| |
Keywords: | Glimepiride Metformin Diabetic nephropathy Plasminogen activator inhibitor 1 Tissue-type plasminogen activator |
本文献已被 维普 等数据库收录! |